Trinity Biotech PLC (NASDAQ:TRIB) released its quarterly earnings data on Thursday. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by $0.03, Morningstar.com reports. Trinity Biotech PLC had a positive return on equity of 5.00% and a negative net margin of 98.39%. The firm had revenue of $25.45 million during the quarter, compared to analyst estimates of $24.83 million.
Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded down 1.2098% during trading on Friday, reaching $6.0509. The company’s stock had a trading volume of 15,909 shares. The company’s market cap is $133.74 million. The stock’s 50 day moving average price is $5.85 and its 200 day moving average price is $5.94. Trinity Biotech PLC has a 52 week low of $5.20 and a 52 week high of $13.68.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Lapides Asset Management LLC raised its position in Trinity Biotech PLC by 9.9% in the first quarter. Lapides Asset Management LLC now owns 1,284,100 shares of the company’s stock valued at $7,653,000 after buying an additional 115,300 shares during the period. First Wilshire Securities Management Inc. raised its position in Trinity Biotech PLC by 21.7% in the first quarter. First Wilshire Securities Management Inc. now owns 1,075,221 shares of the company’s stock valued at $6,408,000 after buying an additional 191,650 shares during the period. Renaissance Technologies LLC raised its position in Trinity Biotech PLC by 21.1% in the first quarter. Renaissance Technologies LLC now owns 164,650 shares of the company’s stock valued at $981,000 after buying an additional 28,700 shares during the period. Hunter Associates Investment Management LLC raised its position in Trinity Biotech PLC by 11.6% in the first quarter. Hunter Associates Investment Management LLC now owns 464,750 shares of the company’s stock valued at $2,770,000 after buying an additional 48,250 shares during the period. Finally, Nine Chapters Capital Management LLC bought a new position in Trinity Biotech PLC during the first quarter valued at $183,000. 66.30% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have commented on the company. Zacks Investment Research downgraded Trinity Biotech PLC from a “buy” rating to a “hold” rating in a report on Wednesday, June 28th. ValuEngine downgraded Trinity Biotech PLC from a “hold” rating to a “sell” rating in a report on Friday, June 2nd.
Trinity Biotech PLC Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.
